Careers  |  Sign In  |  Register

How Will This New Drug Reduce the Risk of Kidney Transplant Rejection?


John Weinberg, MD, COO, Veloxis Pharmaceuticals describes the challenges of organ transplantation. While advancements in the field have minimized the short-term risks of transplantation, the average kidney transplant only lasts about 10-12 years. According to Weinberg, the transience of kidney transplants is often a result of poor compliance with medication and various toxicities such as: tremor, insomnia, diabetes, hypertension and renal dysfunction. Envarsus, which is a new drug in development, is designed to prevent rejection of kidney transplants. Envarsus is a reformulation of the current gold standard medication, tacrolimus, and has been proven to be as effective with half the dosing, in addition to lowering peak concentration